Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Pharma
Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia
Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.
Angus Liu
Sep 25, 2026 9:38am
Boehringer Ingelheim divests biologics CDMO unit in China
Sep 24, 2026 11:38am
Bayer sells cancer drug Stivarga to Grünenthal for up to $431M
Sep 21, 2026 10:20am
US' China deal policy, WCLC, Legend CEO—Fierce Pharma Asia
Sep 18, 2026 10:20am
Legend Biotech names Novartis veteran Ingrid Zhang as new CEO
Sep 16, 2026 10:12am
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Sep 13, 2026 8:00am
